References
- 1. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2(9): 762-764.10.1038/ni0901-76211526378
- 2. Goldenberg MM. Multiple Sclerosis Review. Pharmacy and Therapeutics 2012; 37(3): 175-184.
- 3. Sospedra M. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.10.1146/annurev.immunol.23.021704.11570715771584
- 4. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nature Review Immunology 2015; 15(9): 545-558.10.1038/nri387126250739
- 5. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, Lundstrom W, Greiner E, DessaSadovnick A, Goossens D, Van Broeckhoven C, Del-Favero J, Ebers GC, Oostra BA, VanDuijn CM, Hintzen RQ. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis’’, Nature Genetics 2008; 40(12): 1402-1403.
- 6. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. PLoS one 2010; 5(9): e12496.10.1371/journal.pone.0012496293169620824132
- 7. Yadav V, Shinto L, Bourdette D. Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol 2010; 6(3): 381-395.10.1586/eci.10.12290123620441425
- 8. Yadav V, Narayanaswami P. Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary. Clin Ther 2014; 36(12): 1972-1978.10.1016/j.clinthera.2014.10.01125467189
- 9. Davis PH. Flora of Turkey and the east Aegean islands. Edinburgh University Press 1965.
- 10. Arslan R, Bektas N, Ozturk Y. Antinociceptive activity of methanol extract of fruits of Capparis ovata in mice. Journal of Ethnopharmacology 2010; 131(1): 28-32.10.1016/j.jep.2010.05.06020595018
- 11. Tlili N, Trabelsi H, Renaud J, Khaldi A, Mayer PM, Triki S. Triacylglycerols and phospholipids composition of caper seeds (Capparis spinosa). Journal of the American Oil Chemists’ Society 2011; 88(11): 1787-1793.10.1007/s11746-011-1855-3
- 12. Panico AM, Cardile V, Garufi F, Puglia C, Bonina F, Ronsisvalle G. Protective effect of Capparis spinosa on chondrocytes. Life Sci 2005; 77(20): 2479-2488.10.1016/j.lfs.2004.12.05115946691
- 13. Sen A, Topcu G, Ozgun O, Kolak U, Hacibekiroglu I, Celik G, Arslan S. Anti-neuroinflammatory effect of butanolic subextract of Capparis ovata water extract used as an alternative and complementary treatment for multiple sclerosis. Journal of Neuroimmunology 2014; 275: 172-173.10.1016/j.jneuroim.2014.08.464
- 14. Ozgun- Acar O, Celik-Turgut G, Gazioglu I, Kolak U, Ozbal S, Ergur BU, Arslan S, Sen A, Topcu G. Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL6 mice. Journal of Neuroimmunology 2016; 298: 106-116.10.1016/j.jneuroim.2016.07.010
- 15. Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. European Journal of Neurology 2016; 23(1): 18-27.10.1111/ene.12883
- 16. Brochet B, Guinot P, Orgogozo JM, Ginkgolide Study Group in Multiple Sclerosis. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. Journal of Neurology1995; 58: 360-362.10.1136/jnnp.58.3.360
- 17. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacology & Therapeutics 2002; 95(2): 165-174.10.1016/S0163-7258(02)00255-3
- 18. Lovera J, Bagert B, Smoot K, Morris CD, Frank R, Bogardus K, Wild K, Oken B, Whitham R, Bourdette D. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. MultScler 2007; 13(3): 376-85.10.1177/135245850607121317439907
- 19. Keating GM. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 2017; 77(5): 563-574.10.1007/s40265-017-0720-628293911
- 20. Gabay O, Sanchez C, Salvat C, Chevy F, Breton M, Nourissat G, Wolf C, Jacques C, Berenbaum F. Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. Osteoarthritis and Cartilage 2010; 18(1): 106-116.10.1016/j.joca.2009.08.01919786147
- 21. Tajouri L, Fernandez F, Griffiths LR. (). Gene Expression Studies in Multiple Sclerosis. Current Genomics 2007; 8(3): 181-189.10.2174/138920207780833829243535218645602
- 22. Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005; 12(1): 49-54.10.1111/j.1468-1331.2004.00951.x15613147
- 23. Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur J Neurol 2007; 14(2): 162-167.10.1111/j.1468-1331.2006.01629.x17250724
- 24. Le Moan N, Baeten KM, Rafalski VA, KyuRyu J, RiosCoronado PE, Bedard C, Akassoglou K. HypoxiaInducible Factor-1α in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease. E Neuro 2015; 2(2): 1-12.
- 25. Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, Schimrigkand S, Epplen JT. Inhibitors in the NFκB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes and Immunity 2002: 3, 211-219.10.1038/sj.gene.636384612058256
- 26. Podbielska M, Banik NL, Kurowska E, Hogan EL. Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination. Brain Sciences 2013; 3(3): 1282-1324.10.3390/brainsci3031282406187724961530